Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Leo Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI North America Online

              Participation Not Confirmed

              Update your events

              LEO Pharma Starts first Phase 3 Clinical Trial with Delgocitinib Cream in Adult Patients with Moderate-To-Severe Chronic Hand Eczema

              Contact the Supplier

              Lead Product(s): Delgocitinib

              Therapeutic Area: Dermatology Product Name: LEO 124249

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2021

              Details:

              Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.

              Leo Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI North America Online

              Participation Not Confirmed

              Update your events

              LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis

              Contact the Supplier

              Lead Product(s): Tralokinumab

              Therapeutic Area: Dermatology Product Name: Adtralza

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable